Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from EUDA Health Holdings ( (EUDA) ) is now available.
On October 23, 2025, Wong Kong Yew resigned from his roles at EUDA Health Holdings Limited, including as an independent director and Chairman of the Compensation Committee. His resignation was amicable, with no disputes involved. Subsequently, Huang Bo was appointed as an independent director and took over the roles previously held by Prof. Wong, effective October 24, 2025. Huang Bo’s background includes significant management experience in biotechnology and technology firms, and his current role as General Manager of Shenzhen Key Lock Biotechnology Co., Ltd. is not seen as a conflict of interest in his new position at EUDA.
The most recent analyst rating on (EUDA) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on EUDA Health Holdings stock, see the EUDA Stock Forecast page.
More about EUDA Health Holdings
EUDA Health Holdings Limited operates in the healthcare industry, focusing on the distribution of stem cell therapies and cell immunotherapies in Singapore and Malaysia. The company collaborates with Guangdong Key Lock Health Management Co., Ltd., a key business partner responsible for its current distribution rights.
Average Trading Volume: 119,244
Technical Sentiment Signal: Sell
Current Market Cap: $87.69M
For a thorough assessment of EUDA stock, go to TipRanks’ Stock Analysis page.